XERS Stock Analysis Today
Updated Nov 14, 2026 · trends, key levels, insider activity and news
Is XERS bullish or bearish today?
Daily trend: Uptrend (confirmed) — turns down below $9.04
SEPT signal: Institutional Drive · Strong Bullish
Research grade: B+ · fair value $6.25 (+7.6%)
XERS trend by timeframe
| Daily | Uptrend (confirmed) |
|---|---|
| 4 hour | Strong Bullish |
| 1 hour | Strong Bullish |
| 15 min | Strong Bullish |
| 5 min | Bearish |
Trends are calculated from price structure and update during market hours.
XERS support and resistance levels
Resistance (above)
$17.383 touches
$18.882 touches
$20.281 touches
Support (below)
$16.572 touches
$15.293 touches
$12.944 touches
Upside zones: $16.36 / $16.58 / $16.79
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 1430-day net
-$773KHedge fund holders
208Latest XERS news and filings
- AnalystBenzinga
Barclays keeps Overweight rating on Xeris Biopharma, lifts target to $18
Barclays stayed positive on Xeris Biopharma Holdings and raised its price target to $18. The rating and target change reflect the bank's updated view on the stock.
- NewsFiscal.ai
Xeris Biopharma insider sells shares valued at $312,215
An insider at Xeris Biopharma sold company stock worth $312,215. Insider sales can reflect personal financial decisions, though they are often watched as a signal about management's view.
- AnalystFiscal.ai
Oppenheimer lifts its target for Xeris Biopharma shares to $21
Oppenheimer now expects Xeris Biopharma stock to reach $21, up from its earlier level. The firm updated its view on the biopharmaceutical company.
- SEC FilingSECXeris Biopharma Holdings, Inc. filed an insider trading report (Form 4)
Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.
- AnalystBenzinga
Oppenheimer keeps Outperform rating on Xeris Biopharma, lifts target to $21
Oppenheimer repeated its Outperform rating on Xeris Biopharma Holdings and raised its price target to $21. The change reflects the analyst's updated view of the stock.
- AnalystBenzinga
Piper Sandler keeps Neutral rating on Xeris Biopharma, lifts target to $12
Piper Sandler repeated its Neutral stance on Xeris Biopharma Holdings and moved its price target up to $12. The update reflects the firm's current view on the stock.
- AnalystBenzinga
HC Wainwright keeps Buy rating on Xeris Biopharma, lifts target to $18
HC Wainwright & Co. repeated its Buy rating on Xeris Biopharma Holdings and raised its price target to $18. The change reflects the firm's updated view on the stock.
Live XERS chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Why did XERS stock move on Nov 5, 2026?
Nov 5, 2026: Xeris Biopharma reported Q3 2026 adjusted EPS of $0.06 and sales of $106.267 million, both beating analyst estimates, and raised its full-year 2026 sales outlook to $395M-$405M from a prior $385M-$390M range. The company also projected fiscal 2030 revenue above $1 billion, up from its previous $750 million forecast.
Is XERS bullish or bearish today?
XERS daily trend: Uptrend (confirmed) — turns down below $9.035. SEPT signal: Institutional Drive (Strong Bullish). Updated Nov 14, 2026.
What is XERS's trend on each timeframe?
Daily: Uptrend (confirmed); 4 hour: Strong Bullish; 1 hour: Strong Bullish; 15 min: Strong Bullish; 5 min: Bearish.
What are XERS support and resistance levels?
Support: $16.57, $15.29, $12.94. Resistance: $17.38, $18.88, $20.28. Last price $16.66.
Are insiders buying or selling XERS?
Insider signal: Sell. Last 30 days: 0 buys, 14 sells, net -$773K. 208 hedge funds hold XERS.
What is the latest news on XERS?
Nov 11, 2026: Barclays keeps Overweight rating on Xeris Biopharma, lifts target to $18 · Nov 7, 2026: Xeris Biopharma insider sells shares valued at $312,215 · Nov 6, 2026: Oppenheimer lifts its target for Xeris Biopharma shares to $21